Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

ALPMF's expanding lineup of cancer drugs, including zolbetuximab, positions them for substantial market growth and potential appreciation.

During a Targeted Oncology Case Based Peer Perspectives event, Thomas Hutson, DO, PharmD, discussed the case of a 66-year old woman with bladder cancer that presented post chemotherapy. Enfortumab ...

Leslie Ballas and Tian Zhang discuss the STAR-EV trial, a new study combining enfortumab vedotin (EV) and radiation for muscle-invasive bladder cancer patients ineligible for cisplatin. Dr. Zhang ...

Bladder cancer refers to the growth of a ... has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab ...

If you frequently wake up to go to the bathroom during the night, you may have nocturia. Nocturia refers to having an overactive bladder at night, and can be frustrating and difficult to live with – ...

Michael Menna, DO, is currently an attending emergency medicine physician at White Plains Hospital in White Plains, New York, with nearly 10 years of experience. Rich Scherr is an updates ...

Padcev (enfortumab vedotin-ejfv) is a brand-name infusion prescribed for urothelial cancer (a type of bladder cancer). As with other drugs, Padcev can cause side effects, such as rash and hair loss.

Botox is a prescription drug that’s used to treat certain bladder problems, such as overactive bladder (OAB) in adults. For certain bladder problems, Botox may also be prescribed to children ...

Tisotumab vedotin (TV) shows promise for treating patients with recurrent or metastatic cervical cancer (r/mCC), having received recent FDA approval for second-line use in these cases. Researchers ...

We work right across the cancer research pathway with strengths ranging from cell biology to healthcare research. We aim to nurture the thought leaders of today and tomorrow through the provision of ...